JP2021525749A5 - - Google Patents
Info
- Publication number
- JP2021525749A5 JP2021525749A5 JP2020566789A JP2020566789A JP2021525749A5 JP 2021525749 A5 JP2021525749 A5 JP 2021525749A5 JP 2020566789 A JP2020566789 A JP 2020566789A JP 2020566789 A JP2020566789 A JP 2020566789A JP 2021525749 A5 JP2021525749 A5 JP 2021525749A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- rharg
- abd
- arginine
- abd094
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091527A JP2024116237A (ja) | 2018-05-31 | 2024-06-05 | 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678300P | 2018-05-31 | 2018-05-31 | |
| US62/678,300 | 2018-05-31 | ||
| PCT/CN2019/089583 WO2019228510A1 (en) | 2018-05-31 | 2019-05-31 | Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091527A Division JP2024116237A (ja) | 2018-05-31 | 2024-06-05 | 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525749A JP2021525749A (ja) | 2021-09-27 |
| JP2021525749A5 true JP2021525749A5 (https=) | 2022-07-19 |
| JP7576262B2 JP7576262B2 (ja) | 2024-10-31 |
Family
ID=68697862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566789A Active JP7576262B2 (ja) | 2018-05-31 | 2019-05-31 | 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用 |
| JP2024091527A Pending JP2024116237A (ja) | 2018-05-31 | 2024-06-05 | 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091527A Pending JP2024116237A (ja) | 2018-05-31 | 2024-06-05 | 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200181597A1 (https=) |
| EP (2) | EP4616911A3 (https=) |
| JP (2) | JP7576262B2 (https=) |
| KR (1) | KR20210016434A (https=) |
| CN (2) | CN112513099A (https=) |
| AU (2) | AU2019275733B2 (https=) |
| BR (1) | BR112020024227A2 (https=) |
| CA (1) | CA3101667A1 (https=) |
| ES (1) | ES3049232T3 (https=) |
| IL (2) | IL278993B2 (https=) |
| SG (1) | SG11202011838XA (https=) |
| TW (2) | TWI804691B (https=) |
| WO (1) | WO2019228510A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12508306B2 (en) | 2018-04-25 | 2025-12-30 | Washington University | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders |
| AU2019275733B2 (en) * | 2018-05-31 | 2025-07-31 | The Chinese University Of Hong Kong | Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities |
| EP3823994A4 (en) * | 2018-07-19 | 2022-04-20 | Ab Studio Inc. | Novel systems for screening internalizing antibody and uses thereof |
| WO2020081994A1 (en) | 2018-10-19 | 2020-04-23 | Aerase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
| KR20220082813A (ko) | 2019-08-30 | 2022-06-17 | 아이글레아 바이오테라퓨틱스, 인크. | 인간 재조합 아르기나아제 1의 제조 방법 및 이의 사용 |
| US20210162028A1 (en) * | 2019-12-02 | 2021-06-03 | The Hong Kong Polytechnic University | Methods for Inducing Intermittent Fasting and Modulating Autophagy |
| JP7520121B2 (ja) * | 2019-12-18 | 2024-07-22 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | シュウ酸カルシウム結石形成のリスクにあるコンパニオンアニマルを特定する方法、及び当該リスクを減少させるための治療と組成物 |
| JP2023522888A (ja) * | 2020-04-17 | 2023-06-01 | バイオ－キャンサー・トリートメント・インターナショナル・リミテッド | アルギナーゼを使用してウイルス感染症を処置する方法 |
| WO2021257523A1 (en) * | 2020-06-15 | 2021-12-23 | Aeglea Biotherapeutics, Inc. | Use of arginase for treatment of influenza infections |
| WO2022195629A1 (en) * | 2021-03-18 | 2022-09-22 | National Institute Of Pharmaceutical Education And Research (Niper) | Engineered arginase constructs, method of generation and uses thereof |
| CN118201954A (zh) * | 2021-09-20 | 2024-06-14 | 克云生物科技股份公司 | 精氨酸酶-胰岛素融合蛋白 |
| CN120383669B (zh) * | 2025-04-24 | 2025-10-28 | 广东医科大学 | 一种重组人长效白细胞介素-22结合蛋白的制备方法及应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196195A (en) * | 1990-03-27 | 1993-03-23 | Cornell Research Foundation, Inc. | Use of arginase to control nitric oxide formation |
| AU5192498A (en) * | 1996-12-03 | 1998-06-29 | Kyowa Hakko Kogyo Co. Ltd. | Tissue fibrosis inhibitor |
| US6183738B1 (en) * | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
| WO2002009741A1 (en) * | 2000-07-27 | 2002-02-07 | Angiolab, Inc. | The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis |
| HK1053577A2 (en) * | 2002-06-20 | 2003-10-10 | Bio-Cancer Treatment International Limited | Pharmaceutical composition and method of treatment of human malignanices with arginine deprivation |
| JP2005538709A (ja) * | 2002-06-20 | 2005-12-22 | バイオ−キャンサー・トリートメント・インターナショナル・リミテッド | アルギニンを欠乏させることによってヒト悪性腫瘍を治療する医薬品及び方法 |
| EP1667724A2 (en) * | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| BR122019021416A2 (https=) * | 2003-09-19 | 2019-12-21 | ||
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| WO2006125632A2 (en) * | 2005-05-24 | 2006-11-30 | Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh | Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy |
| CA2742497C (en) | 2008-10-31 | 2024-01-23 | George Georgiou | Compositions of engineered human arginases and methods for treating cancer |
| DK2786762T3 (da) * | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| AU2010242422B2 (en) * | 2009-03-26 | 2014-12-04 | The Hong Kong Polytechnic University | Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents |
| WO2011008495A2 (en) * | 2009-06-29 | 2011-01-20 | The Board Of Regents Of The University Of Texas System | Arginase formulations and methods |
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| CN106456723B (zh) | 2014-04-29 | 2021-03-09 | 康达医药科技有限公司 | 采用精氨酸酶i调节免疫系统的方法和组合物 |
| WO2015177175A2 (en) * | 2014-05-22 | 2015-11-26 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| WO2016044656A1 (en) * | 2014-09-17 | 2016-03-24 | Ansun Biopharma, Inc. | Treatment of infection by human enterovirus d68 |
| MX2018013546A (es) * | 2016-05-06 | 2019-04-22 | Phasebio Pharmaceuticals Inc | Proteinas de fusion de elp para liberacion controlada y sostenida. |
| US12508306B2 (en) * | 2018-04-25 | 2025-12-30 | Washington University | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders |
| AU2019275733B2 (en) * | 2018-05-31 | 2025-07-31 | The Chinese University Of Hong Kong | Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities |
| WO2020081994A1 (en) * | 2018-10-19 | 2020-04-23 | Aerase, Inc. | Arginine depletion therapy for treatment of gamt deficiency |
-
2019
- 2019-05-31 AU AU2019275733A patent/AU2019275733B2/en active Active
- 2019-05-31 EP EP25191849.6A patent/EP4616911A3/en active Pending
- 2019-05-31 EP EP19811035.5A patent/EP3802621B8/en active Active
- 2019-05-31 JP JP2020566789A patent/JP7576262B2/ja active Active
- 2019-05-31 BR BR112020024227-6A patent/BR112020024227A2/pt unknown
- 2019-05-31 CN CN201980051125.8A patent/CN112513099A/zh active Pending
- 2019-05-31 WO PCT/CN2019/089583 patent/WO2019228510A1/en not_active Ceased
- 2019-05-31 CA CA3101667A patent/CA3101667A1/en active Pending
- 2019-05-31 ES ES19811035T patent/ES3049232T3/es active Active
- 2019-05-31 IL IL278993A patent/IL278993B2/en unknown
- 2019-05-31 US US16/427,593 patent/US20200181597A1/en active Pending
- 2019-05-31 SG SG11202011838XA patent/SG11202011838XA/en unknown
- 2019-05-31 CN CN202310876042.0A patent/CN116920081A/zh active Pending
- 2019-05-31 KR KR1020207037922A patent/KR20210016434A/ko active Pending
- 2019-10-25 TW TW108138739A patent/TWI804691B/zh active
- 2019-10-25 TW TW112116955A patent/TWI868683B/zh active
-
2024
- 2024-06-05 JP JP2024091527A patent/JP2024116237A/ja active Pending
-
2025
- 2025-09-09 IL IL323251A patent/IL323251A/en unknown
- 2025-10-31 AU AU2025259974A patent/AU2025259974A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7576262B2 (ja) | 癌、肥満、代謝障害及び関連する合併症と併存症のためのアルギニン枯渇剤の組成と応用 | |
| JP2021525749A5 (https=) | ||
| JP6704358B2 (ja) | 代謝障害を治療するための組成物および使用方法 | |
| EP2531597B1 (en) | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof | |
| EA036985B1 (ru) | Композиции и способы лечения метаболических расстройств | |
| JP7729842B2 (ja) | ｒｈＦＧＦ２１融合タンパク質、ｒｈＦＧＦ２１融合タンパク質をコードするポリヌクレオチド、ｒｈＦＧＦ２１融合タンパク質を含有する組成物、及びｒｈＦＧＦ２１融合タンパク質の使用 | |
| KR102680776B1 (ko) | 고호모시스테인혈증 및 호모시스틴뇨증 환자를 치료하기 위한 인간-효소 매개된 호모시스테인의 고갈 | |
| EP1049487B1 (en) | Treatment of acute intermittent porphyria (aip) and other porphyric diseases | |
| RU2826185C2 (ru) | Композиция и применение истощающих запасы аргинина средств при раке, ожирении, метаболических нарушениях и связанных с ними осложнениях и сопутствующих заболеваниях | |
| HK40101360A (zh) | 用於癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用 | |
| JP2022505689A (ja) | 治療的使用のための、遺伝子操作された霊長類シスチン／システイン分解酵素 | |
| HK40016122A (en) | Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria |